Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease

NCT06958536 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06958536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06958536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR442970 in Adults With Moderate to Severe Crohn's Disease
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
June 3, 2025
Completion date
October 17, 2029
Enrollment
99 (estimated)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease